In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Insmed (INSM), with a price target of $52. The company’s shares closed yesterday at $28.26.
Fein noted:
“Our price target of $52/share is based on: (a) $56/share, as a 35x multiple of taxed and diluted FY28 GAAP EPS of $7.14 discounted back to and (b) an NPV of $47/share, with discount rate 12.0% and growth rate 2%, with both methods arriving at this target. Risks to our investment thesis and target price include: (1) failure of ALIS in the (2) failure of ALIS to achieve peak commercial revenue estimates in our model due to market size, penetration rates and/or pricing or other limiting factors.”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.3% and a 43.7% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Insmed has an analyst consensus of Strong Buy, with a price target consensus of $43.57, a 54.2% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock with a $56 price target.
See today’s analyst top recommended stocks >>
Based on Insmed’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $74.15 million. In comparison, last year the company had a GAAP net loss of $68.52 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
